Reuters logo
in 2 months
BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval
May 15, 2017 / 8:55 PM / in 2 months

BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

1 Min Read

May 15 (Reuters) - Akebia Therapeutics Inc

* Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

* Vifor Pharma will also make a $50 million equity investment in akebia at $14 per share

* Vifor to exclusively distribute vadadustat to Fresenius Medical Care North America for use solely within dialysis facilities in U.S. Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below